Literature DB >> 30701614

HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies.

Francesco Bussu1,2, Luca Tagliaferri3, Giancarlo Mattiucci3, Claudio Parrilla1, Davide Rizzo2, Maria Antonietta Gambacorta3,4, Valentina Lancellotta5, Rosa Autorino3, Carla Fonnesu2, Caterina Kihlgren2, Jacopo Galli1, Gaetano Paludetti1, György Kovács6, Vincenzo Valentini3.   

Abstract

BACKGROUND: Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed.
METHODS: Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases.
RESULTS: Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%).
CONCLUSION: HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  HDR; brachytherapy; head and neck cancer; interventional radiotherapy; nose vestibule

Mesh:

Year:  2019        PMID: 30701614     DOI: 10.1002/hed.25646

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  4 in total

Review 1.  INTERACTS (INTErventional Radiotherapy ACtive Teaching School) consensus conference on sarcoma interventional radiotherapy (brachytherapy) endorsed by AIRO (Italian Association of Radiotherapy and Clinical Oncology).

Authors:  Luca Tagliaferri; Andrea Vavassori; Valentina Lancellotta; Vitaliana De Sanctis; Cristiana Vidali; Calogero Casà; Cynthia Aristei; Domenico Genovesi; Barbara Alicja Jereczek-Fossa; Alessio Giuseppe Morganti; György Kovács; Jose Luis Guinot; Agata Rembielak; Daniela Greto; Maria Antonietta Gambacorta; Vincenzo Valentini; Vittorio Donato; Renzo Corvò; Stefano Maria Magrini; Lorenzo Livi
Journal:  J Contemp Brachytherapy       Date:  2020-08-21

2.  Prevalence of HPV Infection and p16INK4a Overexpression in Surgically Treated Laryngeal Squamous Cell Carcinoma.

Authors:  Roberto Gallus; Tarik Gheit; Dana Holzinger; Marco Petrillo; Davide Rizzo; Gianluigi Petrone; Francesco Miccichè; Gian Carlo Mattiucci; Damiano Arciuolo; Giampiero Capobianco; Giovanni Delogu; Vincenzo Valentini; Massimo Tommasino; Francesco Bussu
Journal:  Vaccines (Basel)       Date:  2022-01-27

3.  Treatment tolerability and outcomes in elderly patients with head and neck cancer.

Authors:  Daniel R Dickstein; Marc Egerman; Erica Monrose; Achintya Varma; Umut Ozbek; Sonam Sharma; Jerry T Liu; Vishal Gupta; Marshall R Posner; Krzysztof Misiukiewicz; Brett A Miles; Eric Genden; Richard L Bakst
Journal:  Head Neck       Date:  2020-12-08       Impact factor: 3.821

4.  SKIN-COBRA (Consortium for Brachytherapy data Analysis) ontology: The first step towards interdisciplinary standardized data collection for personalized oncology in skin cancer.

Authors:  Valentina Lancellotta; Josè Luis Guinot; Bruno Fionda; Agata Rembielak; Alessandro Di Stefani; Stefano Gentileschi; Francesco Federico; Ernesto Rossi; Benjamin Guix; Artur Jan Chyrek; Arenas Meritxell; Silvia Rodriguez Villalba; Giuseppe Ferdinando Colloca; Nicola Dinapoli; Carlotta Masciocchi; Jacopo Lenkowicz; Nicola Dino Capocchiano; Andrea Damiani; Vincenzo Valentini; Gyorgy Kovács; Luca Tagliaferri
Journal:  J Contemp Brachytherapy       Date:  2020-04-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.